Last reviewed · How we verify
AST-120 (Kremezin®)
AST-120 is an oral adsorbent that binds uremic toxins and other waste products in the gastrointestinal tract to reduce their systemic absorption and accumulation.
AST-120 is an oral adsorbent that binds uremic toxins and other waste products in the gastrointestinal tract to reduce their systemic absorption and serum levels. Used for Chronic kidney disease (CKD) to slow progression and reduce uremic toxin burden, End-stage renal disease (ESRD) in dialysis patients.
At a glance
| Generic name | AST-120 (Kremezin®) |
|---|---|
| Also known as | Kremezin®, sopherical carbon adsorbent |
| Sponsor | Astellas Pharma Inc |
| Drug class | Oral adsorbent |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
Mechanism of action
AST-120 (activated charcoal) works as a non-systemic adsorbent that traps protein-bound uremic toxins and other metabolic waste products in the intestinal lumen, preventing their reabsorption and reducing serum levels. By lowering the burden of uremic toxins, it may slow the progression of renal disease and reduce associated complications in chronic kidney disease patients.
Approved indications
- Chronic kidney disease (CKD) to reduce uremic toxins and slow disease progression
- End-stage renal disease (ESRD) in dialysis patients
Common side effects
- Constipation
- Nausea
- Abdominal discomfort
- Black discoloration of stool
Key clinical trials
- AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease (PHASE4)
- Pharmacokinetic Study of ASP1517 With Kremezin® (PHASE1)
- Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome (PHASE2)
- Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas (PHASE3)
- Drug-Drug Interaction Study of TRK-100STP (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AST-120 (Kremezin®) CI brief — competitive landscape report
- AST-120 (Kremezin®) updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI